Navamedic Extends Nordic Mysimba Distribution Agreement With Azurity for Five Years

Bitget2026/10/20 06:47

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Navamedic extended its agreement with Azurity Pharmaceuticals for Nordic distribution rights to oral obesity treatment Mysimba by five years.
The extension takes effect April 26, 2027, on largely similar terms, with an upfront licensing fee.
Azurity acquired Mysimba in 2026; Navamedic has distributed the treatment in the Nordic region under an exclusive agreement since 2017.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Navamedic ASA published the original content used to generate this news brief via Cision (Ref. ID: 202610200245BITN____UKPR__EN_20261020-BIT-6748-0) on October 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Navamedic Extends Nordic Mysimba Distribution Agreement With Azurity for Five Years

You may also like

Crypto prices